Illumisoft Lighting Corp. · TSXV:UVC
Illumisoft Lighting — Investor Presentation (2026)
21 slides from Illumisoft Lighting's investor presentation, May 17, 2026
Slide 1: Illumisoft: Revolutionizing indoor health through light
——N illumisoft ~~ Revolutionizing \ indoor health MN through light TSX-V : UVC \ Investor presentation
Slide 2: Legal Notice
TSX-V: UVC LEGAL NOTICE Important disclosures. FORWARD-LOOKING INFORMATION This presentation contains "forward-looking information" within the meaning of applicable Canadian secu laws and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of
Slide 3: The Problem
—~ Tsx-v : uve ilumisoft THE PROBLEM Indoor spaces are making people sick, and the world is finally demanding a solution. THE COST OF INACTION WHY NOW 2024-26 FOUR CONVERGING FORCES INFLECTION 01 Indoor air is a health crisis HA\s kill more people than car accidents. indoor transmission drives pande
Slide 4: Our Technology Platform
TSX-V: UVC OUR TECHNOLOGY PLATFORM Two pillars of innovation. —~ ilumisoft Comprehensive lighting solutions that save energy and protect health through our mastery of the light spectrum. HEALTH CANADA REGISTERED UPPER-ROOM GUV 99.7% PATHOGEN KILL Disinfectant light, deployed today. Proven upper-room
Slide 5: The Technology
TSX-V: UVC THE TECHNOLOGY —~ ilumisoft The science of UVC is proven. The problem, until now, was human safety. 254 nm Sanitume 216 nm Sanitux 700-380 4M FOUNDATION e1 / 03 UVC destroys pathogens, physically, not chemically. Short-wavelength UV breaks apart the DNA and RNA of viruses, bacteria, and f
Slide 6: Product Portfolio
—~ Tsx-v : uve ilumisoft PRODUCT PORTFOLIO Our product family. LED LIGHTING REVENUE PRODUCING GERMICIDAL UV ACTIVE REVENUE FAR-UVC LAUNCHING SOON ECOWing SaniLume SaniLux Diffused LED lighting. Industry-leading commercial LED retrofit; 34 | Upper-room Germicidal UV. The only Health Canada-registered
Slide 7: SaniLume: most effective upper-room germicidal UV device
TSX-V: UVC ACTIVE REVENUE 254 NM HEALTH CANADA REGISTERED The most effective upper-room germicidal UV device in the market. Independently validated at the University of Leeds aerobiology chamber, 2022. 201-1994 99.7% 750 ft? EQUIV. AIR ELIMINATION RATE COVERAGE CHANGES / HR CDC ventilation baseline:
Slide 8: Independent Validation: University of Leeds
—~ Tsx-v : uve ilumisoft INDEPENDENT VALIDATION: UNIVERSITY OF LEEDS The most powerful upper-room GUV device on the market. The best performing UV device that has been tested in the aerobiology chamber at the University of Leeds to date. DR. LOUISE FLETCHER SCHOOL OF CIVIL ENGINEERING, UNIVERSITY OF
Slide 9: Commercial Case
TSX-V: UVC COMMERCIAL CASE —~ ilumisoft Validated economics. Mandatory demand. From the CHAIR national economic model, to the unit economics of a tertiary deployment, to the bottom-up North American hospital SAM. CHAIR MODEL + HOSPITAL SECTOR The national policy case. S47.7B ANNUAL SOCIETAL VALUE Re
Slide 10: SaniLux
—~ Tsx-v : uve ilumisoft SANILUX COMING SOON. FAR-uvc / 216 NM A fundamental shift , not an increment. Proprietary 216 nm solid-state Far-UVC. IP owned outright by i) Illumisoft, not licensed excimer. 70x <tmin* MORE POWERFUL KILL TIME Human-safe at 216 nm; cannot penetrate skin or eyes. Unlocks con
Slide 11: Technology Advantage
—~ Tsx-v : uve ilumisoft TECHNOLOGY ADVANTAGE SaniLux vs. conventional Far-UVC, every competitor licenses excimer from one Japanese supplier. R-Zero raised $170M USD and still cannot serve aviation, transit or commercial, hard excimer power limits. SaniLux is solid-state, Watt- range, owned outright
Slide 12: Industry Validation / Blueprint Biosecurity
—~ TSX-V: uve ilumisoft INDUSTRY VALIDATION / BLUEPRINT BIOSECURITY Why Far-UVC is the future of indoor air. Independent assessment by Blueprint Biosecurity, the leading nonprofit advancing pandemic-preparedness infrastructure. Their 266-page Blueprint for Far-UVC report (2025) is the definitive tec
Slide 13: ECOWing
—~ Tsx-v : uve ilumisoft REVENUE PRODUCING DIFFUSED LED ECOWing 60-75% less energy. 167 Im/W of DLC-listed efficiency, engineered and manufactured in Ottawa. The beachhead that opens every door. 34/50 17 40-55% #1 RANKING TOP DLC PATENTS GROSS MARGIN FIXTURES ECOWING DIFFUSED LED Every ECOWing insta
Slide 14: Market Opportunity
—~ Tsx-v : uve ilumisoft MARKET OPPORTUNITY $248B global market / bottom-up path to $100M revenue. INFECTION CONTROL 2024 BY 2034 CAGR UV PENETRATION N. AMERICA SHARE $248B $473B 6.7% 530% 40-49% SANILUME / GUV TODAY SANILUX / FAR-UVC UNPRICED OPTION ECOWING / LED ESTABLISHED REVENUE $9.7B $5.25B ~$
Slide 15: Traction / Trusted by Industry Leaders
—~ Tsx-v : uve ilumisoft TRACTION / TRUSTED BY INDUSTRY LEADERS Government, healthcare, real-estate, already on board. In partnership with Health Canada and the NRC to help establish Workplace 3.0 standards for Federal buildings. nanoua BGO eso AAA Trovest Qs REGULATORY R&D PARTNER REAL ESTATE REAL
Slide 16: Go-to-Market & Scale
TSX-V: UVC GO-TO-MARKET & SCALE Canada first. The world follows the standard. PHASE 01 / NOW ACTIVE Dominate Canada CSA mandate delivers immediate SaniLume procurement across the public sector. CHANNEL Direct + govt TAM 23,500+ facilities CAPACITY 10-15K ulyr, Ottawa 12-MONTH CATALYSTS a @ TSX-V lis
Slide 17: Major Strategic Investment
—~ Tsx-v : uve ilumisoft MAJOR STRATEGIC INVESTMENT Backed by global visionaries. Chris Anderson (Founder of TED) and Rob Reid (Creator of Rhapsody) have made a significant ownership commitment through their joint venture, Resilience Reserve LLC. OWNERSHIP STAKE 19 43 % Chris Anderson & Rob Reid / R
Slide 18: About Illumisoft
—~ Tsx-v : uve ilumisoft ABOUT ILLUMISOFT Ottawa-built. Engineered across every wavelength that matters. A Canadian photonics company with two commercial product lines, one breakthrough R&D program, and a leadership team drawn from public markets, semiconductor physics, and global-health venture cap
Slide 19: Capital Structure and Use of Proceeds
TSX-V UVC CAPITAL STRUCTURE PRO-FORMA SHARES OUTSTANDING Capitalization at listing. Claranova shares to shareholders Gstaad post-consolidation (5:1) Concurrent financing (up to $7M @ $0.30) Finder warrants Bridge debenture (due May 4, 2026) FULLY DILUTED / MAX FINANCING ~47,476,806 22,261,805 1,881,
Slide 20: Investment Thesis
TSX-V: UVC INVESTMENT THESIS Six reasons. Why illumisoft. TODAY MANDATORY Mandatory market, today Canadian CSA Z317.12:25 mandates UV. SaniLume is the only registered device. Structural demand, not cyclical. BACKED 19.43% Mission-aligned backers Chris Anderson (TED, $6.6B+ Audacious) and Rob Reid ch
Slide 21: Illumisoft
ilumisoft Proven technology. Mandatory market. Generational entry point. WEB CONTACT REGISTERED ©6060 TICKER illumisoft.com [email protected] Ottawa, Canada TSX-V : UVC